MRD-guided care improves survival

In this episode, Solomon Moshkevich, president of clinical diagnostics at Natera, discusses how molecular data, MRD testing, and AI-driven tools are transforming clinical decision making across oncology, prenatal care, and chronic kidney disease. He shares insights on evidence generation, system integration, and the opportunities ahead for more personalized, cost-effective care.

This episode is sponsored by Natera.